Psychedelics & Mental Health Treatment
•12 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (12)
%
| Company | Market Cap | Price |
|---|---|---|
|
Company focuses on psychedelic-based mental health therapies (psychedelics & mental health treatment).
|
$1.05B |
$5.23
+1.16%
|
|
MindMed's portfolio centers on psychedelic-based therapeutics for brain health and neuropsychiatric disorders.
|
$892.28M |
$11.81
-5.75%
|
|
GH Research's lead and pipeline focus on 5-MeO-DMT psychedelic therapies for depression, a neuropsychiatric/mental health domain.
|
$655.03M |
$12.59
-4.48%
|
|
COMPASS Pathways is developing proprietary psychedelic therapy (COMP360) for treatment-resistant depression and PTSD, which aligns with the Psychedelics & Mental Health Treatment investable theme.
|
$581.95M |
$6.22
-4.31%
|
|
Sage Therapeutics focuses on brain health medicines and neuropsychiatric/neurodevelopmental therapies, aligning with the Psychedelics & Mental Health Treatment theme.
|
$544.94M |
N/A
|
|
Uses psychedelic-inspired structures and targets in neuropsychiatric care, fitting Psychedelics & Mental Health Treatment.
|
$282.52M |
$63.29
+2.58%
|
|
Cybin develops psychedelic-based therapeutics for mental health (CYB003, CYB004) and related EMBARK psychotherapy ecosystem, fitting 'Psychedelics & Mental Health Treatment'.
|
$120.41M |
$6.02
-5.05%
|
|
Ketamine-based and psychedelic‑assisted mental health approaches are part of NRX's focus in psychiatry, aligning with Psychedelics & Mental Health Treatment.
|
$54.81M |
$3.17
-11.70%
|
|
PSX-001 is a psilocybin-based psychedelic therapy for Generalized Anxiety Disorder, aligning with psychedelics/mental health investable themes.
|
$11.53M |
$0.39
-9.33%
|
|
CMND is developing psychedelic-derived therapeutics and mental health treatments.
|
$3.70M |
$0.93
-5.00%
|
|
Company's pipeline includes psychedelic-based therapeutics for PTSD and mental health, aligning with Psychedelics & Mental Health Treatment.
|
$2.52M |
$0.56
-16.31%
|
|
Enveric is pursuing psychedelic-derived neuropsychiatric therapeutics with non-hallucinogenic neuroplastogen profiles.
|
$1.71M |
$0.68
-1.76%
|
Loading industry metrics...
Loading comparison data...
